- First patient dosed in Phase 1/2 trial for lead candidate ATR 1072 targeting PRKAG2 syndrome.
- Study to enroll ~37 participants with initial proof-of-concept data expected in H2 2027.
?? Positive AI Sentiment (+2.0 / 10)
Single signal · #10072
$RNA — AI Filing Signal
Public delayed archive entry for this Stock Catalyst AI alert.